LELars Edenbrandt

Lars Edenbrandt

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Lars Edenbrandt has a total of 96 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Bone Scan Index as an imaging biomarker to predict overall survival in the Zeus/SPCG11 study.

    by Mariana Reza, Manfred Wirth, Teuvo L. J. Tammela, Virgilio Cicalese, Francisco Gomez Veiga, Kurt Miller, Andrea Tubaro, Frans Debruyne, Anup Patel, Christien Caris, et al.

    E16599 Background: The Zeus/SPCG11 study is a randomized controlled clinical trial with the aim to assess the efficacy of zoledronic acid (ZA) in preventing bone metastases in high-risk prostate cancer (PCa) patients. Bone Scan Index (BSI) reflects the tumour burden in bone calculated from bone scintigraphy, and has recently been validated as an imaging biomarker in metastatic PCa patients. The purpose of this study was to investigate if change in BSI during treatment may serve as a useful imaging biomarker to predict clinical outcome in the Zeus/SPCG11 study population. Methods: We retrospectively selected as our BSI-study cohort all patients with bone scan image data of sufficient quality to allow for both baseline and 48-months follow-up BSI-assessments. BSI data was obtained by using the automated quantification software EXINI boneBSI, in a blind fashion, without knowledge of any clinical data or treatment randomization. Clinical data on age, overall survival (OS) and prostate-specific antigen (PSA) concentration in blood at baseline and upon follow-up was collected separately. Association between clinical data and BSI change during treatment was evaluated using Cox proportional-hazards regression models, Kaplan-Meier estimates of the survival function and Log rank test. Discrimination between prognostic variables was assessed using the concordance index (C-index). Results: The 176 patients who fulfilled the inclusion criteria presented showed baseline characteristics similar to those of the final total Zeus/SPCG11 study population (N = 1,433)(p= 0.83). In our BSI-study cohort (N = 176), patients with a BSI change < 0.3 had a significantly longer median survival time compared to patients with BSI increase of > 0.3 (32.3 months and 18.2 months respectively) (p < 0.001). In the Cox analysis BSI change from baseline to follow-up was significantly associated with OS (p < 0.01 and C-index = 0.6) while age and PSA change were not significantly associated with OS. Conclusions: BSI change during treatment was associated with OS in high-risk PCa patients from the Zeus/SPCG11 study. BSI may be a useful imaging biomarker in future clinical trials involving PCa patients with bone metastases.

  • Automated bone scan index as a quantitative imaging biomarker indicative of efficacy to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC).

    by Aseem Anand, Michael J. Morris, Steven M. Larson, Mattias Ohlsson, Andreas Joseffson, John Thomas Helgstrand, Lars Edenbrandt, Peter Sander Oturai, M. Andreas Roeder, Anders Bjartell

    226 Background: The automated BSI (auto-BSI) is a computerized means of quantitatively expressing tumor burden in bone. Following the analytical validation of auto-BSI, we are now clinically qualifying the tool as a response biomarker in mCRPC. In the present study, we assess the association of auto-BSI and that of PSA with overall survival (OS) in mCRPC patients (pts) being treated with enzalutamide. Methods: All mCRPC pts who initiated enzalutamide treatment at Skåne Hospital, Sweden and at Rigshospitalet, Denmark, with a minimum of one year follow-up, were eligible for the study. Eligible mCRPC pts with baseline (BL) bone scan available before starting enzalutamide were enrolled in the study. PSA, hemoglobin (Hgb) and alkaline phosphatase (ALP) were obtained at BL. Treatment follow-up PSA and auto-BSI were obtained at week-12. auto-BSI was obtained using the analytically validated EXIN boneBSIversion 2.0. Cox regression and concordance index (c-index) were used to evaluate the association with OS. Results: 80 mCRPC pts with BL bone scans were enrolled in the study. Treatment follow-up bone scans were available from 62 pts. Univariate analysis demonstrated that auto-BSI, PSA, ALP and Hgb at BL were associated with OS (p < 0.0001). In the multivariate analysis, only auto-BSI and HgB were significantly associated with OS. The auto-BSI showed the highest c-index in prediction of OS (c-index 0.72, SE 0.03). Adding auto-BSI to the BL covariate model significantly improved the discrimination from c-index 0.67 to 0.72 (p < 0.05). At treatment follow-up, the univariate analysis of the change in auto-BSI and the percent change in PSA were strongly associated with OS with c-index 0.76 and 0.72 (SE 0.05), respectively. In bivariate analysis, the change in auto-BSI remained strongly associated with OS (p < 0.0001) whereas the percent change in PSA appeared to be less so (p = 0.07). Conclusions: Auto-BSI and its change demonstrated an independent and a strong association with OS in mCRPC pts being treated with enzalutamide. The study serve as a foundation for prospective validation of auto-BSI as an imaging biomarker indicative of efficacy to enzalutamide.

  • Open Access

    Perfusion vector—a new method to quantify myocardial perfusion scintigraphy images: a simulation study with validation in patients

    by David Minarik, Martin Senneby, Per Wollmer, Alva Mansten, Karl Sjöstrand, Lars Edenbrandt, Elin Trägårdh

    The interpretation of myocardial perfusion scintigraphy (MPS) largely relies on visual assessment by the physician of the localization and extent of a perfusion defect. The aim of this study was to introduce the concept of the perfusion vector as a new objective quantitative method for further assisting the visual interpretation and to test the concept using simulated MPS images as well as patients. The perfusion vector is based on calculating the difference between the anatomical centroid and the perfusion center of gravity of the left ventricle. Simulated MPS images were obtained using the SIMIND Monte Carlo program together with XCAT phantom. Four different-sized anterior and four lateral defects were simulated, and perfusion vector components x-, y-, and z-axes were calculated. For the patient study, 40 normal and 80 abnormal studies were included. Perfusion vectors were compared between normal and abnormal (apical, inferior, anterior, and lateral ischemia or infarction) studies and also correlated to the defect size. For simulated anterior defects, the stress perfusion vector component on the y-axis (anterior-inferior direction) increased in proportion to the defect size. For the simulated lateral defects, the stress perfusion vector component on the x-axis (septal-lateral direction) decreased in proportion to the defect size. When comparing normal and abnormal patients, there was a statistically significant difference for the stress perfusion vector on the x-axis for apical and lateral defects; on the y-axis for apical, inferior, and lateral defects; and on the z-axis (basal-apical direction) for apical, anterior, and lateral defects. A significant difference was shown for the difference vector magnitude (stress/rest) between normal and ischemic patients (p = 0.001) but not for patients with infarction. The correlation between the defect size and stress vector magnitude was also found to be significant (p < 0.001). The concept of the perfusion vector introduced in this study is shown to have potential in assisting the visual interpretation in MPS studies. Further studies are needed to validate the concept in patients.


  • Bone scan index as a biomarker to predict outcome in real-life mCRPC patients on abiraterone acetate: A multicenter study.

    by Mariana Reza, Mattias Ohlsson, Reza Kaboteh, Aseem Anand, Ingela Franck Lissbrant, Jan-Erik Damber, Lars Budäus, Till Eichenauer, Per Wollmer, Lars Edenbrandt, et al.

    217 Background: Bone Scan Index (BSI) is a quantitative measurement that reflects the tumor burden in bone calculated from bone scintigraphy. It also represents a prognostic marker in patients (pts) with metastatic castration resistant prostate cancer (mCRPC). Abiraterone acetate (AA) has showed to prolong survival before and after chemotherapy in this group of pts. In this study we evaluated the predictive value of BSI change as a biomarker of response in mCRPC patients on treatment with AA. Methods: We retrospectively studied 62 mCRPC pats who received AA following disease progression after chemotherapy at 3 different academic hospitals. Automated baseline and follow-up BSI data was obtained from images of whole-body bone scintigraphies performed before and during AA treatment. Data on clinical overall survival (OS), blood levels of prostate-specific antigen (PSA), alkaline phosphatase (ALP) and haemoglobin (Hb) at the time of baseline and upon follow-up was collected from medical records. The association between changes in these parameters at follow-up and survival was evaluated using Cox proportional-hazards regression models and Kaplan-Meier estimates of the survival function. Discrimination between prognostic variables was assessed using the concordance index (C-index). Results: Pts with an increase in BSI of > 0.3 (n=31) had 13% one year-survival rate compared to 42% for pts with improvement or stable disease according to BSI change at follow-up (BSI change < 0.3; n=31) (p< 0.001). Among all parameters evaluated (BSI, PSA, ALP, Hb) in a univariate Cox analysis, BSI change from baseline to follow-up presented the highest and strongest association with OS (C-index=0.7, Hazard ratio= 1.3 and p=0.0001). Conclusions: Increase in BSI of ≥ 0.3 is significantly associated with reduced survival in mCRPC pts under AA treatment following disease progression in a post-chemotherapy setting. BSI is a candidate biomarker to evaluate response and survival in this group, and change in BSI could be a valuable tool in monitoring pts with mCRPC on second-line therapies. BSI could then serve as a decision making tool supporting physicians to continue current treatment or to consider alternative therapies.

  • Open Access

    Evaluation of inter-departmental variability of ejection fraction and cardiac volumes in myocardial perfusion scintigraphy using simulated data

    by Elin Trägårdh, Michael Ljungberg, Lars Edenbrandt, Eva Örndahl, Lena Johansson, Agneta Gustafsson, Cathrine Jonsson, Jessica Hagerman, Katrine Riklund, David Minarik

    Myocardial perfusion scintigraphy (MPS) is a clinically useful noninvasive imaging modality for diagnosing patients with suspected coronary artery disease. By utilizing gated MPS, the end diastolic volume (EDV) and end systolic volume (ESV) can be measured and the ejection fraction (EF) calculated, which gives incremental prognostic value compared with assessment of perfusion only. The aim of this study was to evaluate the inter-departmental variability of EF, ESV, and EDV during gated MPS in Sweden. Seventeen departments were included in the study. The SIMIND Monte Carlo (MC) program together with the XCAT phantom was used to simulate three patient cases with different EDV, ESV, and EF. Individual simulations were performed for each department, corresponding to their specific method of performing MPS. Images were then sent to each department and were evaluated according to clinical routine. EDV, ESV, and EF were reported back. There was a large underestimation of EDV and ESV for all three cases. Mean underestimation for EDV varied between 26% and 52% and for ESV between 15% and 60%. EF was more accurately measured, but mean bias still varied between an underestimation of 24% to an overestimation of 14%. In general, the intra-departmental variability for EDV, ESV, and EF was small, whereas inter-departmental variability was larger. Left ventricular volumes were generally underestimated, whereas EF was more accurately estimated. There was, however, large inter-departmental variability.


  • Open Access

    Bone Scan Index as a prognostic imaging biomarker during androgen deprivation therapy

    by Mariana Reza, Anders Bjartell, Mattias Ohlsson, Reza Kaboteh, Per Wollmer, Lars Edenbrandt, Elin Trägårdh

    Bone Scan Index (BSI) is a quantitative measurement of tumour burden in the skeleton calculated from bone scan images. When analysed at the time of diagnosis,it has been shown to provide prognostic information on survival in men with metastatic prostate cancer (PCa). In this study, we evaluated the prognostic value of BSI during androgen deprivation therapy (ADT). Prostate cancer patients who were at high risk of a poor outcome and who had undergone bone scan at the time of diagnosis and during ADT were recruited from two university hospitals for a retrospective study. BSI at baseline and follow-up were calculated using an automated software package (EXINIbonebsi).Associations between BSI, other prognostic biomarkers and overall survival (OS)were evaluated using a Cox proportional hazards regression model. One hundred forty-six PCa patients were included in the study. A total of 102patient deaths were registered, with a median survival time after the follow-up bone scan of 2.4 years (interquartile range (IQR) =0.8 to 4.4). Both at baseline and during ADT, BSI was significantly associated with OS in univariate and multivariate analyses. When BSI was added to a prognostic base model including age, prostate-specific antigen, clinical tumour stage and Gleason score, the concordance index increased from 0.73 to 0.77 (p =0.0005) at baseline and from 0.77 to 0.82 (p <0.0001) during ADT. Automated BSI during ADT is an independent prognostic indicator of OS in PCa patients with bone metastasis. It represents an emerging imaging biomarker that can be used in a prognostic model for risk stratification of PCa patients at the time of diagnosis and at later stages of the disease. BSI could then help physicians identify patients who could benefit from more aggressive therapies.


  • Open Access

    Analysis of regional bone scan index measurements for the survival of patients with prostate cancer

    by Jonas Kalderstam, May Sadik, Lars Edenbrandt, Mattias Ohlsson

    A bone scan is a common method for monitoring bone metastases in patients with advanced prostate cancer. The Bone Scan Index (BSI) measures the tumor burden on the skeleton, expressed as a percentage of the total skeletal mass. Previous studies have shown that BSI is associated with survival of prostate cancer patients. The objective in this study was to investigate to what extent regional BSI measurements, as obtained by an automated method, can improve the survival analysis for advanced prostate cancer.


  • Increase in bone scan index during abiraterone treatment in relation to reduced survival in mCRPC patients.

    by Mariana Reza, Anders Bjartell, Mattias Ohlsson, Lars Edenbrandt, Elin Tragardh

    244 Background: Abiraterone acetate (AA) is one of several new treatment options for patients with metastatic castration-resistant prostate cancer (mCRPC). It has showed to prolong survival in patients who had disease progression after chemotherapy. An objective biomarker that is associated with improvement in survival would be of value in the management of patients under AA treatment, for example in decisions to continue or change treatment. Bone Scan Index (BSI) is a measurement that reflects the tumor burden in bone as a percent of the total skeletal mass. The purpose of this study was to evaluate BSI as a response biomarker in mCRPC patients on treatment with AA. Methods: We retrospectively studied a consecutive series of 28 mCRPC patients who received AA following disease progression after chemotherapy. All patients had undergone whole-body bone scan before and during AA treatment. Baseline and follow-up BSI data was obtained using the automated quantification software EXINI Bonebsi(EXINI Diagnostics AB, Sweden). Data on prostate-specific antigen (PSA) and survival were collected from the medical records. Cox proportional-hazards regression models and Kaplan-Meier estimates of the survival function were used to investigate the association between changes in BSI and PSA from baseline to follow-up and survival. Discrimination between prognostic variables was assessed using the concordance index (C-index). Results: Patients with an increase in BSI of at least 0.2 (n=15) had a worse one-year survival (36%) than those with improvement or stable disease (BSI change <0.2) (96%) (p< 0.006). Both follow-up BSI and the BSI change from baseline to follow-up showed higher C-index (0.80) than the corresponding PSA values (0.73 and 0.75). Conclusions: Increase in BSI is significantly associated with reduced survival in mCRPC patients under AA treatment following disease progression after chemotherapy. Calculation of BSI could be a valuable tool for treatment response evaluation as a complement to the traditional methods. [Table: see text]

  • Open Access

    Area of ischemia assessed by physicians and software packages from myocardial perfusion scintigrams

    by Lars Edenbrandt, Peter Höglund, Sophia Frantz, Philip Hasbak, Allan Johansen, Lena Johansson, Annett Kammeier, Oliver Lindner, Milan Lomsky, Shinro Matsuo, et al.

    The European Society of Cardiology recommends that patients with >10% area of ischemia should receive revascularization. We investigated inter-observer variability for the extent of ischemic defects reported by different physicians and by different software tools, and if inter-observer variability was reduced when the physicians were provided with a computerized suggestion of the defects.


  • Open Access

    Prognosis of patients without perfusion defects with and without rest study in myocardial perfusion scintigraphy

    by Lars Edenbrandt, Mattias Ohlsson, Elin Trägårdh

    Background: Stress myocardial perfusion scintigraphy (MPS) is widely regarded as a useful imaging modality for diagnosing patients with suspected ischemic heart disease. Current European guidelines recommend stress study to be performed first since rest study can be omitted if stress study is interpreted as normal. Thus, a rest study should only be performed in patients with equivocal or abnormal studies. The aim of the present study was to investigate the prognosis of a normal stress-only MPS compared to a normal stress-rest MPS in a retrospective manner and also with regard to normal/abnormal left ventricular function data. Methods: All 4,820 patients who underwent 99mTc MPS at Skåne University Hospital in Malmö, Sweden, in 2004 to 2007, for suspected or management of known ischemic heart disease were considered. The physician in clinical charge of the investigation decided whether a rest study was necessary or not. Based on the final report according to clinical routine, only patients with a normal perfusion study (no infarction or inducible ischemia) were included. The endpoints were non-fatal acute coronary syndrome or death from ischemic cardiac origin. Results: A total of 3,426 patients with a normal perfusion study were included. Of these, 2,215 patients had a stress-only study and 1,211 patients had both stress and rest studies. Mean follow-up was 6.2 years. The lowest event rate was found in the normal stress-only group (0.56% for normal stress-only patients vs. 1.42% for normal stress-rest patients; p < 0.0001). When dividing patients according to sex and stress type, the best prognosis was also found in the normal stress-only group (p < 0.0001 for all comparisons). Regarding left ventricular function data, we did not find any significant difference in event rate between normal vs. abnormal ejection fraction (EF), normal vs. abnormal end-diastolic volume (EDV) or normal EF, and EDV vs. abnormal EF or EDV for either the normal stress-only patients or the normal stress-rest patients. Conclusions: Patients with a normal stress-only study had an excellent prognosis over a mean follow-up time of 6 years. Thus, omitting the rest study if the stress study is normal is a safe procedure.